| Literature DB >> 27837436 |
Jasdeep Dhami1, Edwin Chang2, Sanjiv S Gambhir3.
Abstract
Within the Ayurvedic medical tradition of India, Ashwagandha (Withania somnifera) is a well-known herb. A large number of withanolides have been isolated from both its roots and its leaves and many have been assessed for their pharmacological activities. Amongst them, Withaferin A is one of its most bioactive phytoconstituents. Due to the lactonal steroid's potential to modulate multiple oncogenic pathways, Withaferin A has gained much attention as a possible anti-neoplastic agent. This review focuses on the use of Withaferin A alone, or in combination with other treatments, as a newer option for therapy against the most aggressive variant of brain tumors, Glioblastoma. We survey the various studies that delineate Withaferin A's anticancer mechanisms, its toxicity profiles, its pharmacokinetics and pharmacodynamics and its immuno-modulating properties.Entities:
Keywords: Anticancer; Ashwagandha; Glioblastoma; Immunomodulation; Oncogenic pathways; Pharmacodynamics; Pharmacokinetics; Pharmacological; Withaferin A; Withania somnifera; Withanolides
Mesh:
Substances:
Year: 2016 PMID: 27837436 DOI: 10.1007/s11060-016-2303-x
Source DB: PubMed Journal: J Neurooncol ISSN: 0167-594X Impact factor: 4.130